Welcome to our dedicated page for Scworx SEC filings (Ticker: WORX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SCWorx Corp (NASDAQ: WORX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including Forms 10-K, 10-Q, 8-K, and proxy statements. As a healthcare data management and interoperability SaaS provider for hospitals and health systems, SCWorx uses these filings to report on corporate governance, financing arrangements, listing status, and other material events.
In its Form 8-K current reports, SCWorx has described matters such as notices from the Nasdaq Stock Market regarding the minimum bid price requirement, extensions to regain compliance, and the potential use of a reverse stock split approved by shareholders. Other 8-K filings detail warrant inducement agreements, issuance of new warrants, and related unregistered sales of equity securities, including the terms under which existing warrant holders exercised warrants and received new warrants.
The company’s DEF 14A definitive proxy statement outlines proposals presented to shareholders, including the election of directors, advisory votes on executive compensation, ratification of its independent registered public accounting firm, authorization of share issuances under Nasdaq Listing Rule 5635(d), an increase in authorized share capital, and approval of an equity incentive plan. The proxy materials also describe the annual meeting logistics, record date, quorum requirements, and voting standards.
Through its periodic reports on Forms 10-K and 10-Q, SCWorx provides audited and reviewed financial statements and related disclosures, and has discussed delays in certain filings along with the engagement of a new independent registered public accounting firm to complete audit and review work. These documents are central for understanding the company’s financial condition, risk factors, and operational narrative as a healthcare SaaS data management provider.
On this page, users can access SCWorx filings as they are made available through EDGAR, and use AI-powered tools to quickly interpret key elements of 10-K and 10-Q reports, track material 8-K events, and review proxy-related information relevant to WORX shareholders.
SCWorx Corp. Schedule 13G/A discloses that Iroquois Capital Management, LLC, Richard Abbe and Kimberly Page report beneficial interests in the issuer through outstanding warrants and convertible notes. The filing shows reported aggregates of 403,850 shares for Richard Abbe (reported as 9.99% of the class) and 305,524 shares for each of Iroquois Capital and Kimberly Page (reported as 7.75% of the class). These reported amounts include shares issuable upon conversion/exercise but are limited by contractual Beneficial Ownership Blockers that restrict conversion/exercise to 4.99% or 9.99% thresholds, so all instruments could not be converted or exercised as reported. Some Convertible Notes convert at a stated conversion price of $0.3496. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest and certify the securities were not acquired to change or influence control of the issuer.